Top Three Considerations for Planning Your Move to the 3DEXPERIENCE Platform

By Matt H.

Over the past year there has been a lot of communication around the new 3DEXPERIENCE platform made available in the R2014x release. Some ENOVIA customers may wonder how this impacts their past investments with Dassault Systèmes. While the R2014x release offers many new benefits to Dassault Systèmes’ customers and upgrading is very similar to past ENOVIA V6 upgrades. The reasons are:

  1. The 3DEXPERIENCE platform is an extension to the ENOVIA platform used in previous releases – in other words, both have the same technology foundation.
  2. All V6 commercial licenses from past releases are migrated to R2014x at no charge and in many cases the new licenses have expanded functionality.
  3. As with past releases, a customer can upgrade with the same functional scope or choose to expand their implementation’s scope with new processes for new user roles.

1. 3DEXPERIENCE Platform Technology

The same data model and business process rules that power the 3DEXPERIENCE platform also powered the ENOVIA platform. In fact, the same basic approach also powered the MatrixOne platform. This is why so many of ENOVIA’s current customers have been able to successfully upgrade since their first implementation in the mid to late 1990’s. This evolution of platform technology is best conveyed in the following figure:

The evolution of platform technology by Dassault Systèmes

The evolution of platform technology

While the “engine” of all 3 evolutions of the platform is very similar, the 3DEXPERIENCE platform’s spans a much broader scope of functionality. In addition to the formal control of product development processes, the 3DEXPERIENCE platform also provides social collaboration and data federation capabilities to either enterprise or public data sources. The 3DEXPERIENCE platform also delivers the latest IT technologies including cloud support and a modern user experience for desktop and mobile devices.

2. License Upgrades

All licenses from past V6 releases are upgraded to R2014x at zero charge as part of the standard V6 maintenance policy. In many cases these upgrades will provide more standard capabilities than customers previously received. For example, the license for Engineering Bill-of-Material Management now includes standard capabilities for managing an approved vendor list, which was previously licensed separately. Another example of the added standard value provided with R2014x is all licenses for managing CAD data now include standard library classification and reuse capabilities. Of course, the best way to learn of the added value of R2014s is to contact a 3DS Sales Executive to arrange a presentation of all the standard benefits in R2014x.

3. Expand and Transform an ENOVIA Implementation w/ R2014x

A customer may choose to upgrade to R2014x just to get the new functionality described in the previous sections. However, over the past few years, ENOVIA has added business processes for many roles beyond PLM’s traditional roots in Engineering and Design departments. Additionally, many of these roles and processes are now uniquely tailored to specific industry needs as delivered in the 3DS Industry Solution Experiences.   The R2014x upgrade is an excellent opportunity to also assess your company’s business goals and determine if there are new processes and user roles that need to be included in the ENOVIA implementation.

Summary

Hopefully, this quick introduction to upgrading to the 3DEXPERIENCE platform has answered many questions, and provides assurance that this upgrade will be similar to all past V6 upgrades. Remember:

  1. The 3DEXPERIENCE represents an evolution of the technology rooted in ENOVIA V6 and the Matrix One platform
  2. Your licenses will migrate to the 3DEXPERIENCE platform – often with additional functionality.
  3. Take advantage of the new technology available in the 3DEXPERIENCE platform to solve new business challenges.

We look forward to working with you to help you get the most out of the 3DEXPERIENCE platform. Be sure to contact one of our solutions experts at enovia.ux.ww@3ds.com for more information.  Additionally, please feel free to comment or ask you questions in the comment section below.

Matthew J. Hall Matthew Hall is the ENOVIA User Advocacy & Social EXPERIENCE Specialist.You can find him on Twitter at @mjhall. Connect with ENOVIA at @3DSENOVIA

Why Products Are No Longer Enough: Consumers Today Buy Experiences

By Therese

Take a minute and think about the products you manufacture. Whether it’s in the area of High Tech, Consumer Goods, Transportation & Mobility, or any other industry, at the end of the day, it’s what motivates consumers to purchase that matters the most. And what motivates them more than the actual experience?

The consumers of today buy experiences—products are no longer enough. At the 3DEXPERIENCE FORUM North America, you can learn how to go beyond delivering great products and move to creating memorable experiences for your customers. Virtual Reality presents a significant impact on your customers and use of DELMIA solutions can take them there. Find out how we can help you manage and deliver the right product experience to your customers around the world.

Manufacturers like you can provide memorable experiences for customers using DELMIA solutions. We’ll help you navigate the future by enabling innovation and collaboration across the business ecosystem. DELMIA provides businesses like yours with 3DEXPERIENCE universes to improve the real world of Global Industrial Operations. Our DELMIA experts will be on hand to show your how you can meet your customers’ expectations for a unique, highly-personal experience tailored to their needs.

3DEXPERIENCE_Forum_Vegas_PMH_Bkft_Nov14

Join Us for the 3DS Brand Leader’s Breakfast with Patrick Michel

Hear more about the latest advancements in manufacturing at the 3DEXPERIENCE Forum North America from DELMIA’s VP of User Experience and Marketing, Patrick Michel. Patrick will reveal how to go beyond delivering great products and move toward creating memorable experiences for your customers. Meet with him on Wednesday November 12 at 7 A.M. to hear how. When registering here, be sure to check the “3DS Brand Leader’s Breakfast” option.

After the forum, continue the technical conversation on Manufacturing. Go where all the experts are. Join the conversation at a DELMIA Community now!

The International Conference on Harmonisation’s Planned Drug Manufacturing Guideline: What Do Pharma Manufacturers Need To Know?

By Jennifer

International Conference on HarmonisationThe International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is an organization that brings together pharmaceutical regulatory authorities in Europe, Japan, and the United States towards the goal of standardizing processes for safe and effective drug discovery and development. On October 10th, 2014, ICH published an initial concept paper for guidance in its Quality category titled ”Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.” The resulting ICH Q12 guideline, due to be available in 2017, will complement existing quality assurance plan guidance in the pharmaceutical development and launch phases with regulatory recommendations in the later chemistry manufacturing and controls (CMC) phase. Adoption of ICH Q12 will benefit patients, pharmaceutical/ biotech companies, and regulators through continual improvement of post approval processes. So what should you do?

In this article, we will review the concept paper as well as to begin to highlight how the 3DEXPERIENCE Platform and the Licensed to Cure for BioPharma industry solution experience can help you prepare for, and implement the ICH Q12 guidance. We will follow the ICH Q12 updates closely on the blog, see all posts tagged with ICH here.

Licensedd To Cure For BioPharma

Representation of the solution (example).

While ICH Q12 is a very fitting addition to the organization’s Quality guidelines, the concept paper makes it clear that creation of the guideline is due to unforeseen gaps in the implementation of  ICH Q8-Q11, which are as follows:

 

The ICH Q12 guideline is expected to impact the following areas

  • Regulatory Dossier
    • Updates aimed at improving post approval changes
  • Pharmaceutical Quality System (ICH Q10)
    • Develop improved knowledge and change management systems
  • Post-approval Change Management Plans and Protocols
    • Establish criteria for managing and submitting post-approval changes

 

The benefits of ICH Q12 implementation include

  • Improving reliability of the supply of pharmaceuticals through more CMC change management processes
  • More standardized and useful regulatory dossiers
  • Enhance use of regulatory tools for Post-approval Change Management (PACM)
  • Continual improvement of the manufacturing process
  • Reduction of product variability
  • Increased manufacturing efficiency

 

The benefits of product lifecycle management

At Dassault Systèmes (3DS), we have long recognized the benefits of product lifecycle management in improving the drug manufacturing process and ultimately the patient experience. The Licensed to Cure for BioPharma industry solution experience powered by the 3DEXPERIENCE platform combines advances in collaboration, global product development, and information intelligence to provide operational excellence. This single version of the truth, systematic  approach to drug manufacturing fits well with the ICH Q12 vision, and we look forward to working with biotech and pharma manufacturers to guide them in adapting to these changes. You can learn more about 3DS pharma and biotech solutions by attending the 3DEXPERIENCE Forum—North America, taking place November 12-14, 2014 in Las Vegas.

The ICH Q12 guideline will represent a major change as it will be applicable over the lifecycle of the product and focused on the CMC phase. An Expert Working Group (EWG) will be comprised of assessors and inspectors with expertise in quality systems and pharma manufacturing of chemical, biological, or biotechnological products. The EWG will meet in November 2014, June 2014, and November 2015, with the Adoption of Step 2 Document occurring in Q2 of 2016 and Adoption of Step 4 Document occurring Q2 2017 (see this description for details of the ICH process). Although not all regulatory authorities (such as the Food and Drug Administration, (FDA)) adopt the ICH Guidelines directly, ICH Q12 will surely impact regulatory requirements globally.



Page 3 of 20712345...102030...Last »
3ds.com

Beyond PLM (Product Lifecycle Management), Dassault Systèmes, the 3D Experience Company, provides business and people with virtual universes to imagine sustainable innovations. 3DSWYM, 3D VIA, CATIA, DELMIA, ENOVIA, EXALEAD, NETVIBES, SIMULIA and SOLIDWORKS are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.